Namodenoson

The FDA granted namodenoson an orphan drug designation for pancreatic cancer treatment. Namodenoson, a small, orally bioavailable drug, targets A3 adenosine receptors on cancer cells, inducing apoptosis. A phase 2 study is planned to evaluate its safety and clinical activity in advanced pancreatic cancer patients. Preclinical studies showed namodenoson significantly inhibited pancreatic cancer cell growth and modulated signaling pathways.

FDA grants orphan drug designation to namodenoson (CF102) for pancreatic cancer, offering Can-Fite BioPharma regulatory advantages. A phase 2 study (NCT06387342) will evaluate namodenoson in advanced pancreatic adenocarcinoma patients, with primary end points focusing on safety and secondary end points including response rates and survival.

Can-Fite BioPharma's Namodenoson granted Orphan Drug Designation by FDA for pancreatic cancer, with plans to start Phase II study by year-end.

The FDA granted orphan drug designation to namodenoson for pancreatic cancer treatment. Namodenoson, targeting A3AR on cancer cells, induces apoptosis and is safe due to A3AR's low expression on normal cells. A phase 2 study is planned to evaluate its safety and clinical activity. Preclinical studies showed significant dose-dependent inhibition of pancreatic cancer cell growth and modulation of signaling pathways, supporting further evaluation.

DelveInsight's 'Hepatocellular Carcinoma Pipeline Insight 2024' report details 90+ companies developing 95+ pipeline drugs for HCC, with therapies in various stages of clinical development, including collaborations and regulatory approvals.